Valley View company begins clinical study with University of Cincinnati

A few weeks after receiving additional patent coverage, Great Lakes NeuroTechnologies has launched a clinical study to assess the sensitivity of their Kinesia system to detect subtle motor function changes in patients with Parkinson’s disease (PD). The NIH-funded study is being conducted in partnership with Dr. Alberto Espay of the University of Cincinnati and Dr. Peter LeWitt of HenryFord Health System in Detroit.

Researchers and companies around the world are investigating new treatments intended to slow the progression of PD. Demonstrating the efficacy of these types of proposed neuroprotective therapies can be challenging since very small changes over long periods of time must be measured. The current standard for evaluation of PD motor symptom severity and progression is the Unified Parkinson’s Disease Rating Scale (UPDRS), a subjective scoring system relying on clinician observations to rate symptom severity on 0-4 scale.

Using a system like Kinesia, with high sensitivity motion sensors to measure those changes, can provide several advantages when combined with clinical rating scales. As a unique part of the study design, Parkinson’s patients implanted with deep brain stimulation devices will be recruited for the study. Slowly adjusting the stimulation settings will allow researchers to simulate worsening symptoms and disease progression that would normally take years to study.

Learn more about the clinical study in the company’s press release.

Recent Posts

Blog Post Archive

Blog Post Categories

Search the Blog

Newsticker


BioOhio Member Mark BioOhio Member

Enable Injections featured in article on safer, simpler, smarter devices for drug delivery | Drug Development & Delivery, September 15, 2014

BioOhio takes 2014 Annual Conference “on the road” in series of three regional events | Business Wire, September 15, 2014

ABC’s of IND’s – ChanTest to Host Session at the Safety Pharmacology Society (SPS) Annual Meeting | PR Web, September 15, 2014

Nationwide Children’s Hospital discusses Enterovirus D68 | Nationwide Children's Hospital, September 12, 2014

Akebia Therapeutics (NASDAQ: AKBA) to ring the NASDAQ Stock Market Opening Bell | NASDAQ, September 11, 2014

$1M grant to Cincinnati Children’s intended to improve human growth and development around the world | CCHMC, September 10, 2014

Airway Therapeutics gets money to advance treatment for smallest and sickest babies | WCPO9 Cincinnati, September 10, 2014

Airway Therapeutics raises $4.6M in Series A financing | CincyTech, September 10, 2014

Airway Therapeutics announces $4.6M funding round | Cincinnati.com, September 10, 2014

Alkermes anti-addiction drug Vivitrol helping inmates at Barnstable County Correctional Facility (MA) | Boston Business Journal, September 8, 2014

Nationwide Children’s Hospital now home to the world’s largest Ronald McDonald House | Columbus Dispatch, September 8, 2014

Envision Pharmaceutical completes its acquisition of MedTrak Services (Kansas) | Herald Online, September 8, 2014

Ohio Capital Fund key player in state startup scene | Cincinnati.com, September 6, 2014

Navidea enters Lymphoseek development and commercialization agreement with Hainan Sinotau Pharmaceutical Co., Ltd. subsidiary in China | Navidea Pharmaceuticals, September 4, 2014

Ricerca Biosciences in discussions to be acquired | OutsourcingPharma.com, September 3, 2014

Meridian Bioscience signs agreement with Premier to offer its hospitals molecular diagnostic tests and instruments | Business Wire, September 3, 2014

Cleveland Functional Electrical Stimulation Center taking toy donations at Expo to help disabled children | WKYC3 NBC, September 2, 2014

Aerpio Therapeutics announces publication of preclinical data on AKB-9778 for common eye diseases | Business Wire, September 2, 2014

Cleveland, Neuros Medical, featured in US News article on urban revitalization | US News, September 2, 2014

Thanks to smart moves, STERIS stock is on the rise | Crain's Cleveland Business, August 31, 2014